The PURPOSE-1 trial, a phase 3 randomized controlled trial enrolling 5,338 cisgender adolescent girls and young women in South Africa and Uganda (NEJM 2024, n=2,134 in the lenacapavir arm, funded by Gilead Sciences with independent data monitoring), reported zero HIV infections over 52 weeks versus an expected background incidence of 2.4 per 100 person-years. PURPOSE-2, another large RCT in men and gender-diverse individuals, replicated near-perfect efficacy. These high-quality RCTs signal a genuine breakthrough in long-acting PrEP. Yet as the STAT opinion notes, the $28,218 annual list price risks repeating the slow uptake seen with cabotegravir, where four years post-approval it comprises under 3% of PrEP use due to insurer barriers and inventory costs.

The original STAT coverage effectively draws parallels to hepatitis C direct-acting antivirals but underplays the global equity dimension. While Louisiana's subscription model produced a fivefold increase in cures (observational state-level data, Health Affairs 2021), and Australia's program halved HCV deaths versus counterfactuals (peer-reviewed economic evaluation, Lancet Regional Health 2023, no major conflicts), these were domestic programs. The HIV burden is overwhelmingly in low- and middle-income countries facing 2025 U.S. funding slashes to PEPFAR and global research. Subscription models could stabilize costs for governments and insurers without per-patient marginal pricing that triggers prior authorizations.

Synthesizing these with a 2022 Health Affairs analysis of Netflix-style contracts shows such arrangements expand access while preserving manufacturer revenue through volume guarantees, avoiding the innovation chill of blunt price caps. What the STAT piece misses is implementation risk: volatile public budgets, as evidenced by the 2025 cuts, could undermine subscription commitments. Additionally, Gilead's existing voluntary licensing for lenacapavir in low-income countries must be harmonized with middle-income subscription deals to prevent tiered equity gaps.

Overall, the proposed model aligns with the editorial lens that subscription pricing can expand access to this HIV prevention advance while controlling costs and addressing pharmaceutical affordability and equity. It decouples pricing from volume, allowing predictable budgeting for health systems and broader population-level impact beyond what traditional reimbursement has achieved.